

EXHIBIT 2

**UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF NEW YORK**

In re Novartis and Par Antitrust Litigation

1:18-cv-04361-AKH

This Document Relates to:

All Direct Purchaser Actions

**DIRECT PURCHASER PLAINTIFFS' [PROPOSED] PLAN OF
ALLOCATION FOR THE DIRECT PURCHASER CLASS**

Drogueria Betances, LLC (“Betances”), Rochester Drug Co-Operative, Inc. (“RDC”), FWK Holdings, LLC (“FWK”) and KPH Healthcare Services, Inc., a/k/a Kinney Drugs, Inc. (“KPH”) (collectively the “Named Plaintiffs” or “Direct Purchaser Class Plaintiffs”), on behalf of the proposed settlement Class,¹ hereby submit this proposed Plan of Allocation to allocate the settlement funds received in the settlement with Novartis, plus any interest earned on the settlement funds, and net of Court-approved attorneys’ fees, any Court-approved named plaintiff

¹ The Class is defined as follows:

All persons or entities in the United States, including its territories, possessions, and the Commonwealth of Puerto Rico, who purchased Exforge directly from Novartis, or who purchased a generic version of Exforge directly from Par, at any time during the Class Period from September 21, 2012, until March 30, 2015 (“Exforge Direct Purchasers”). Excluded from the Class are Novartis and Par and their officers, directors, management and employees, predecessors, subsidiaries and affiliates, and all federal governmental entities.

Also excluded from the Class for purposes of this Settlement Agreement are the following entities: CVS Pharmacy, Inc. (which includes Omnicare), Rite Aid Corporation, Rite Aid Hdqtrs. Corp., Walgreen Co., The Kroger Co. (which includes Peytons), and H-E-B L.P. (“Retailer Plaintiffs”).

”Novartis” means Novartis Pharmaceuticals Corporation and Novartis AG; “Par” means Par Pharmaceutical, Inc.

service awards, and Court-approved expenses, including settlement-related costs and expenses (the “Net Settlement Fund”).

The proposed Plan of Allocation (“Allocation Plan”) allocates the Net Settlement Fund based on each Class member’s *pro rata* share of combined net purchases of brand and generic Exforge tablets purchased directly from Novartis or Par.² This proposal is similar to allocation plans that have been approved in settlements of similar class actions brought by direct purchasers to recover overcharges arising from allegedly impaired generic competition.³

Plaintiffs’ expert, economist Jeffrey J. Leitzinger, Ph.D., can calculate each Class member’s (and eventually, each Claimant’s⁴) percentage share of the Net Settlement Fund using

² See Declaration of Jeffrey J. Leitzinger, Ph.D. Related to Proposed Allocation Plan and Net Settlement Fund Allocation, dated December 28, 2022 (“Leitzinger Allocation Decl.”), at ¶ 3 (filed herewith).

³ See, e.g., *In re Intuniv Antitrust Litig.*, 1:16-cv-12653, ECF Nos. 480-7, 551 (D. Mass.) (*pro rata* shares of settlement fund computed on basis of claimants’ brand and generic purchases); *In re Loestrin 24 FE Antitrust Litig.*, 1:13-md-02472, ECF Nos. 1411-8, 1462 (D.R.I.) (same); *In re Namenda Direct Purchaser Antitrust Litig.*, 1:15-cv-7488, ECF Nos. 919-2, 947 (S.D.N.Y.) (same); *In re Solodyn (Minocycline Hydrochloride) Antitrust Litig.*, 1:14-md-02503-DJC, ECF Nos. 1163-4, 1179 (D. Mass.) (same); *In re Lidoderm Antitrust Litig.*, 3:14-md-02521-WHO, ECF Nos. 1004-5, 1004-6, 1054 (N.D. Cal.) (same); *In re Aggrenox Antitrust Litig.*, No. 14-md-02516, ECF Nos. 733-8, 739 (D. Conn.) (*pro rata* shares of settlement fund computed on basis of purchases); *King Drug of Florence, Inc. v. Cephalon, Inc.*, No. 2:06-cv-01797, ECF Nos. 864-17, 870 (E.D. Pa.) (same); *In re Doryx Antitrust Litig. (Mylan Pharms., Inc. v. Warner Chilcott Public Ltd.)*, No. 2:12-cv-03824, ECF Nos. 452-3, 665 (E.D. Pa.) (same); *In re Tricor Direct Purchaser Antitrust Litig.*, No. 1:05-00340, ECF Nos. 536-1, 543 (D. Del.) (*pro rata* shares of settlement fund computed on basis of claimants’ unit purchases in a product hop case).

⁴ A “Claimant” is any entity that timely submits a completed claim form. A Claimant’s percentage share will be zero if that Claimant timely submits a claim form but that Claimant’s claim is rejected because, for example, the Claimant did not purchase brand or generic Exforge during the relevant time period (described below) and does not have any valid assignment covering any such direct purchases. Allocations to Claimants whose right to settlement allocation arises by virtue of assignment from Class members would be determined in the same fashion as allocation for Class members. In such cases, the volumes of brand and generic purchases used to determine the allocation would be the volumes assigned to the Claimant by an otherwise eligible Class member (and the assignor Class member’s brand and generic purchase volumes would be reduced by the same amount). Leitzinger Allocation Decl. at ¶ 5 n.6. As the

sales data for brand and generic Exforge produced by Novartis and Par in this litigation.⁵

Claimants will also have the option of submitting their own records or data showing their net unit purchases of brand or generic Exforge during the relevant periods described below in, *inter alia*, Section 2.1, along with data regarding any relevant assignment agreement. Dr. Leitzinger and his staff at Econ One will review any such submissions and confer with the Claims Administrator and Class Counsel regarding the final calculations, which may include making any necessary and appropriate adjustments. *See* Leitzinger Allocation Decl. at ¶ 7.

Throughout this Allocation Plan, “purchases” refers to purchases, net of returns or assignments, made directly from Novartis or Par during the relevant time periods or purchases that are covered by a Claimant’s assignment from a Class member covering purchases made directly from Novartis or Par during the relevant time periods.⁶ *Id.* at ¶ 3 n.4 The unit of purchase is a tablet of brand or generic Exforge. *Id.*

As explained more fully below, Claimants’ *pro rata* shares will be based only on purchases of Exforge and/or generic Exforge made directly from Novartis or Par (or covered by an assignment from a Class member) during the relevant time periods. *See id.* at ¶ 3.

The proposed Allocation Plan is practical and efficient, using computerized sales data

Claim Form will make clear, data submitted by a Claimant who files a Claim Form based on an assignment may be shared with the Claimant’s assignor Class member during the claims administration process.

⁵ *See* Leitzinger Allocation Decl. at ¶¶ 5-6. Dr. Leitzinger previously submitted three reports in this matter, which addressed, among other issues, damages and class certification. *See* Expert Report of Jeffrey J. Leitzinger, Ph.D., dated March 30, 2021 (“Report” or “Leitzinger Report”); Supplemental Expert Report of Jeffrey J. Leitzinger, Ph.D., dated April 16, 2021 (“Supplemental Report” or “Supplemental Leitzinger Report”); Supplemental Expert Report of Jeffrey J. Leitzinger, Ph.D., dated December 22, 2021 (“Second Supplemental Report” or “Second Supplemental Leitzinger Report”).

⁶ To be clear, “purchases” do not include branded or generic Exforge purchased, directly or indirectly, from any entity other than Par or Novartis.

already obtained from Novartis and Par during discovery.⁷ It also is a reasonable way to allocate the Net Settlement Fund and is fair to all members of the Class.⁸

THE ALLOCATION PLAN

The Allocation Plan works as follows:

1.1 At the appropriate time and after receiving Court approval, the Claims Administrator, working with Dr. Leitzinger's firm Econ One Research, Inc. ("Econ One"), will provide a separate, individualized claim form (the "Claim Form") for each Class member. The Claim Form will expressly set forth the Class member's purchases of branded and generic Exforge from Par and Novartis during the period of September 21, 2012 through March 29, 2016, specifically: (a) net branded Exforge direct purchases from Novartis from September 21, 2012 through March 29, 2016;⁹ and (b) net generic Exforge direct purchases from Par for the period from September 30, 2014 through March 30, 2015.¹⁰ Dr. Leitzinger can calculate these figures using the sales data produced during discovery by the Novartis and Par.¹¹ The Claim Form will request that the Class member verify the accuracy of the information contained in the

⁷ See Leitzinger Allocation Declaration at ¶ 6.

⁸ See *id.* at ¶ 8.

⁹ September 21, 2012 is the beginning of the Class Period and the beginning of the overcharge period Dr. Leitzinger analyzed in his prior reports. March 29, 2016 is the end of the period for which Dr. Leitzinger measured overcharges on brand Exforge in his prior reports. *Id.* at ¶ 3(a); Second Supplemental Report at Exhibits 18-19.

¹⁰ September 30, 2014 is the first date on which generic Exforge was sold according to the sales data produced by Par in this litigation, and March 30, 2015 is the end of the period for which Dr. Leitzinger measured overcharges on generic Exforge in his prior reports. Leitzinger Allocation Decl. at ¶ 3(b).

¹¹ See Leitzinger Allocation Declaration at ¶¶ 5-6 (explaining that these totals can be calculated from the sales data produced in this case, and that he has already performed preliminary calculations of each Class member's net purchases that account for known assignments to the Retailer Plaintiffs that have previously opted out of the Class).

Claim Form and will provide instructions for challenging any of the figures or computations contained in the Claim Form. If a Class member agrees that the information in the Claim Form is accurate, it will be asked to sign and return the Claim Form to the Claims Administrator.¹² If a Class member believes that the information contained in its Claim Form is not accurate, that Class member may submit its own purchase data pursuant to the procedures described below.

1.2 The Claim Form will request the Claimant's full name and mailing address for correspondence regarding the distribution of the Net Settlement Fund and the identity and contact information for the person responsible for overseeing the claims process for the Claimant. In addition, the Claim Form will include the release language contained in the Settlement Agreement with Novartis. Each Claimant will be required to execute the Claim Form in exchange for receiving any distribution from the Net Settlement Fund.

1.3 *Timeliness.* The submission of the Claim Form to the Claims Administrator (with any necessary supporting documentation if the Claimant disagrees with the information contained in its Claim Form) will be deemed timely if it is received or postmarked within 30 days of the date Claim Forms are mailed.

2. Calculation of Weighted *Pro Rata* Shares of the Net Settlement Fund.

2.1 Each Claimant's allocated share of the Net Settlement Fund will be set in proportion to each Claimant's combined total purchase volumes of (a) branded Exforge direct purchases from Novartis from September 21, 2012 through March 29, 2016; and (b) generic Exforge direct purchases from Par from September 30, 2014 through March 30, 2015; net of any

¹² In order to help the Claimant verify that the purchase totals contained in the Claim Form are accurate, the brand and generic Exforge National Drug Codes ("NDCs") will be listed on the Claim Form. The NDCs are standard codes maintained by the FDA and used in the pharmaceutical industry to identify specific pharmaceutical products and allow Claimants to understand precisely what purchases are being considered for purposes of allocation.

returns or assignments.¹³ The Net Settlement Fund is then allocated to each Claimant based upon its percentage share of the total purchase volumes across all Claimants who submit valid, accepted Claims Forms.¹⁴

2.2 The allocation computation will be based on the following information (whether from the data already produced in discovery or from submissions by Claimants): (a) each Claimant's net branded Exforge purchases from Novartis from September 21, 2012 through March 29, 2016; and (b) each Claimant's net generic Exforge purchases from Par from September 30, 2014 through March 30, 2015.¹⁵

2.4 To calculate the *pro rata* share for each Claimant of the Net Settlement Fund, the Claims Administrator, working with Dr. Leitzinger, will take (a) each Claimant's combined total net purchases of branded Exforge from Novartis from September 21, 2012 through March 29, 2016 and generic Exforge from Par from September 30, 2014 through March 30, 2015, (b) remove any purchases for which the rights to damages in this litigation have been assigned by agreement, and divide it by (c) the combined total purchases by all Claimants who timely submit valid, accepted Claim Forms of brand Exforge from Novartis from September 21, 2012 through March 29, 2016, and generic Exforge from Par from September 30, 2014 through March 30, 2015. This calculation will yield each Claimant's *pro rata* share of the Net Settlement Fund.¹⁶ Using data produced in discovery, Dr. Leitzinger has already performed a preliminary computation of net brand Exforge purchases from Novartis (September 21, 2012 through March

¹³ Leitzinger Allocation Declaration at ¶ 5. The dates utilized in this Plan of Allocation are explained above in Section 1.1 and footnotes 9-10.

¹⁴ Leitzinger Allocation Declaration at ¶ 5(e).

¹⁵ *Id.* at ¶ 5.

¹⁶ *Id.* at ¶ 5.

29, 2016) and net generic Exforge purchases from Par (September 30, 2014 through March 30, 2015) for each Class member, and can use these figures to calculate the percentage shares of the Net Settlement Fund due to each Class member.¹⁷ Should any Class member fail to submit a claim or should any Claimant document and submit an alternative amount of purchases that is approved by the Claims Administrator (in consultation with Dr. Leitzinger and Class Counsel), the Claimant's shares will be recalculated accordingly.¹⁸

2.5 The final calculations of each Claimant's *pro rata* share will then be applied to the Net Settlement Fund to determine each Claimant's allocated share (in dollars).

3. Processing of Claims.

3.1 All Claims will be reviewed and processed by the Claims Administrator, with assistance from Dr. Leitzinger and his staff at Econ One as required and appropriate.

3.2 *Acceptance and Rejection.* The Claims Administrator shall first determine whether a Claim Form received is timely, properly completed, and signed. If a Claim Form is incomplete, the Claims Administrator shall communicate with the Claimant via First Class Mail, email, or telephone regarding the deficiency. The Claims Administrator may also contact Claimants requesting additional documentation or other materials. Claimants will have 28 days from the date they are contacted by the Claims Administrator regarding any question, requests for additional information, deficiency, or any other issue to provide a complete response, the requested documentation or other materials, and/or to cure any such deficiency. If a Claimant fails to adequately respond and/or correct any deficiency within 28 days, its claim may be

¹⁷ See *id.* at ¶ 6. The allocation percentages will be calculated using the same methodology Dr. Leitzinger used in calculating shares in Exhibit 20A of the Second Supplemental Leitzinger Report. Leitzinger Allocation Declaration at ¶ 6.

¹⁸ See *id.* at ¶ 7.

rejected and the Claimant shall be notified by letter stating the reason for rejection. The Claims Administrator will then review all completed, non-deficient Claim Forms to determine whether each will be accepted or rejected and will notify any Claimants whose Claim Forms are rejected by letter stating that the Claimant's Claim Form is rejected and stating the reason for rejection. Any Claimant whose Claim Form is rejected may seek review by the Court via the appeals process described in Section 7.2 below.

3.3 All late Claims Forms that are otherwise complete will be processed by the Claims Administrator but marked as "Late Approved Claims." If Class Counsel conclude that, in their judgment, any such "Late Approved Claims" should ultimately not be accepted,¹⁹ the Claimant will be so notified, and then may seek review by the Court via the appeals process described in Section 7.2 below.

3.4 *The Pro Rata Distribution Calculation.* Dr. Leitzinger and his staff at Econ One, in conjunction with the Claims Administrator and Class Counsel, will be responsible for determining the total amount each Claimant will receive from the Net Settlement Fund. Once the Claims Administrator has determined which claims are approved, Econ One will work with the Claims Administrator to calculate each Claimant's *pro rata* share of the Net Settlement Fund as determined by the calculation described above in Section 2.²⁰

4. Processing Challenged Claims.

4.1 The Claims Administrator, in conjunction with Dr. Leitzinger and his staff

¹⁹ Cf. *Kuehbeck v. Genesis Microchip Inc.*, 2007 WL 2382030, at *1 (N.D. Cal. Aug. 17, 2007) (authorizing distribution to timely filed claims and valid claims that were submitted late). Courts have approved similar provisions in similar generic suppression cases. See, e.g., *In re Solodyn (Minocycline Hydrochloride) Antitrust Litig.*, 1:14-md-02503-DJC, ECF Nos. 1163-4 at § 3.3, 1179 (D. Mass.) (approving a similar provision regarding late claims); *In re Lidoderm Antitrust Litig.*, 3:14-md-02521-WHO, ECF Nos. 1004-5 at § 3.3, 1054 (N.D. Cal.) (same).

²⁰ See Leitzinger Allocation Declaration at ¶¶ 5-7.

at Econ One and Class Counsel, shall review any and all written challenges by Claimants to the determinations of the Claims Administrator. If upon review of a challenge and supporting documentation, the Claims Administrator and Dr. Leitzinger decide to amend or modify their determination, the Claims Administrator shall advise the Claimant who made the challenge. These determinations shall be final, subject to the appeals process described in Section 7.2 below.

4.2 Where the Claims Administrator, in conjunction with Dr. Leitzinger and his staff at Econ One, determines that a challenge requires additional information or documentation, the Claim Administrator will so advise the Claimant and provide that Claimant an opportunity to cure the deficiency within 28 days, as set forth in Section 3.2 above. If that Claimant fails to cure the deficiency within that time, the challenge may be rejected and the Claimant will be notified of the rejection of its challenge by mail, which notification shall be deemed final subject to any appeal and decision by the Court.

4.3 If the Claims Administrator, in conjunction with Dr. Leitzinger and his staff at Econ One, concludes that it has enough information to properly evaluate a challenge and maintains that its initial determinations were correct, it will so inform the Claimant in writing. Such notification shall be deemed final subject to any appeal and decision by the Court.

5. Report to Court Regarding Distribution of Net Settlement Fund.

5.1 After the Claims Administrator reviews all submitted claims and works with Dr. Leitzinger to determine the amount each Claimant is entitled to receive from the Net Settlement Fund, the Claims Administrator will prepare a final report for the Court's review and approval. The report will explain the tasks and methodologies employed by the Claims Administrator in processing the claims and administering the Allocation Plan. It will also

contain (a) a list of Class members or other Claimants (if any) who filed Claim Forms that were rejected and the reasons, (b) a list of challenges (if any) to the estimated distribution amounts that were rejected and the reasons, and (c) the date any such Claimant whose challenge was rejected was informed by the Claims Administrator for purposes of calculating the timeliness of any appeal using the procedures set forth below. Finally, the final report shall contain an accounting of the expenses associated with the Allocation Plan, including bills from Econ One and the Claims Administrator, any taxes that are due and owing, and any other fees or expenses associated with the settlement allocation process.

6. Payment to the Claimants.

6.1 Upon Court approval of the final report and declaration of the Claims Administrator, the Claims Administrator shall issue, with Court approval, a check or wire payable to each Claimant who has submitted a complete and valid Claim Form, including to each Claimant that filed a Late Approved Claim.

6.2 Subject to further order of the Court, any monies from the Net Settlement Fund that remain unclaimed after any initial distribution or additional monies received at a later date pursuant to the Settlement with Novartis shall, if economically feasible, be distributed (with Court approval) to Claimants in an additional distribution or distributions on the basis of the same calculations of the Claimants' *pro rata* combined total of branded and generic Exforge purchases described above.

6.3 Insofar as the Net Settlement Fund includes residual funds after distribution or distributions as set forth in the preceding sections that cannot be economically distributed to the Claimants (because of the costs of distribution as compared to the amount remaining), Class Counsel shall make an application to the Court for such sums to be used to

make *cy pres* payments for the benefit of members of the Class.²¹

7. Resolution of Disputes.

7.1 In the event of any disputes between Claimants and the Claims Administrator on any subject (*e.g.*, timeliness, required completeness or documentation of a claim, or the calculation of the Claimant's unit purchases of branded or generic Exforge, share of the net settlement fund, and/or amount payable), the decision of the Claims Administrator shall be final, subject to the Claimant's right to seek review by the Court. In notifying a Claimant of the final rejection of a Claim or a challenge thereto, the Claims Administrator shall notify the Claimant of its right to seek such review.

7.2 Any such appeal by a Claimant must be submitted in writing to the Court, with copies to the Claims Administrator and Class Counsel, within 21 days of the Claims Administrator's final rejection notification to the Claimant.

Dated: December 28, 2022

Respectfully Submitted,

/s/ Bruce E. Gerstein
Bruce E. Gerstein

²¹ In the experience of Class Counsel, based on numerous prior distributions in similar cases, an application for a *cy pres* distribution is unlikely.

FARUQI & FARUQI, LLP
Kristyn Fields
685 Third Ave., Floor 26
New York, NY 10017
Tel.: (212) 983-9330
Fax: (212) 983-9331
Email: kfields@faruqilaw.com

FARUQI & FARUQI, LLP
Peter Kohn
Joseph T. Lukens
1617 JFK Blvd., Suite 1550
Philadelphia, PA 19103
Tel: (215) 277-5770
Email: pkohn@faruqilaw.com
Email: jlukens@faruqilaw.com

BERGER MONTAGUE PC
David F. Sorensen
Caitlin G. Coslett
1818 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: (215) 875-3000
Email: dsorensen@bm.net
Email: ccoslett@bm.net

*Attorneys for Plaintiff Rochester Drug Co-
Operative, Inc. and the Direct Purchaser
Class*

KAPLAN FOX & KILSHEIMER, LLP
Robert N. Kaplan
Matthew P. McCahill
Ralph E. Labaton
850 Third Avenue, 14th Floor
New York, New York 10022
Tel: 212-687-1980
Fax: 212-687-7714
Email: rkaplan@kaplanfox.com
Email: mmccahill@kaplanfox.com
Email: rlabaton@kaplanfox.com

SPERLING & SLATER, P.C.
Joseph M. Vanek
David P. Germaine
55 W. Monroe, Suite 3200

GARWIN GERSTEIN & FISHER LLP
Bruce E. Gerstein
Joseph Opper
Dan Litvin
Deborah A. Elman
88 Pine Street, 10th Floor
New York, NY 10005
Tel: (212) 398-0055
Fax: (212) 764-6620
Email: bgerstein@garwingerstein.com
Email: jopper@garwingerstein.com
Email: dlitvin@garwingerstein.com
Email: delman@garwingerstein.com

*Attorneys for Plaintiff Drogueria Betances,
LLC Interim Lead Counsel for the Direct
Purchaser Class*

SMITH SEGURA RAPHAEL & LEGER,
LLP
David Raphael
Erin Leger
Susan Segura
221 Ansley Boulevard
Alexandria, LA 71303
Tel: (318) 445-4480
Fax: (318) 487-1741
Email: draphael@ssrllp.com
Email: eleger@ssrllp.com
Email: ssegura@ssrllp.com

ODOM & DES ROCHES
Stuart Des Roches
Andrew Kelly
Dan Chiorean
Poydras Center
650 Poydras Street, Suite 2020
New Orleans, LA 70130
Tel: (504) 522-0077
Fax: (504) 522-0078
Email: stuart@odrlaw.com
Email: akelly@odrlaw.com
Email: dchiorean@odrlaw.com

HEIM PAYNE & CHORUSH LLP
Russell A. Chorush

Chicago, Illinois 60603
Tel: (312) 641-3200
Fax: (312) 641-6492
Email: jvanek@sperling-law.com
Email: dgermaine@sperling-law.com

1111 Bagby, Suite 2100
Houston, TX 77002
Tel: (713) 221-2000
Fax: (713) 221-2021
Email: rchorush@hpcllp.com
Email: mjones@hpcllp.com

*Attorneys for Plaintiff FWK Holdings, LLC
and the Direct Purchaser Class*

*Attorneys for Plaintiff Drogueria Betances,
LLC and the Direct Purchaser Class*

ROBERTS LAW FIRM, P.A.
Michael L. Roberts
20 Rahling Circle
Little Rock, AR 72223
Telephone: (501) 821-5575
Facsimile: (501) 821-4474
mikeroberts@robertslawfirm.us

*Attorneys for Plaintiff KPH Healthcare
Services, Inc., a/k/a Kinney Drugs, Inc.
and the Direct Purchaser Class*

CERTIFICATE OF SERVICE

I hereby certify that on December 28, 2022, I, Bruce E. Gerstein, served the above via ECF on counsel of record.

Respectfully Submitted,

/s/ Bruce E. Gerstein
Bruce E. Gerstein